Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Increasing evidence indicates that locally blocking renin–angiotensin system activity exerts a beneficial effect on glomerulonephritis (GN) progression leading to irreversible glomerulosclerosis. This is the first study on the pharmacological effect of the renal delivery of aliskiren, a direct renin inhibitor, in a progressive model of anti-Thy-1 GN.
Local blockade of renin activity was accomplished by subrenal capsular implantation of a collagen sponge with aliskiren. The pharmacological effect was evaluated by semiquantitative and quantitative analysis of immunohistological findings and by analysis of glomerular microcirculation using an intravital microscope system.
Quantitative mesangial matrix analysis showed that local treatment with aliskiren significantly suppressed mesangial matrix expansion and ameliorated the glomerular sclerotic index in the progressive model of ATS GN. Immunofluorescent studies revealed that renin expression at the juxtaglomerular region was enhanced in the ATS + aliskiren group, and pathological expressions of α-smooth muscle cell actin and type I collagen in ATS GN were remarkably decreased by local treatment with aliskiren. Furthermore, local delivery of aliskiren significantly improved glomerular blood flow levels.
This study revealed that renally delivered aliskiren has a renoprotective effect on potentially progressive glomerulosclerosis.
- Prieto-Carrasquero, MC, Kobori, H, Ozawa, Y, Gutierrez, A, Seth, D, Navar, LG (2005) AT1 receptor-mediated enhancement of collecting duct rennin in angiotensin II-dependent hypertensive rats. Am J Physiol Renal Physiol 289: pp. F632-F637 CrossRef
- Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, et al. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. J Am Soc Nephrol. 2005;16:1775–80.
- Campbell, R, Sangalli, F, Perticucci, E, Aros, C, Viscarra, C, Perna, A (2003) Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63: pp. 1094-1103 CrossRef
- Remuzzi, G, Ruggenenti, P, Perna, A, Dimitrov, BD, Zeeuw, D, Hille, DA (2004) Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15: pp. 3117-3125 CrossRef
- Dechow C, Morath C, Peters J, Lehrke I, Waldherr R, Haxsen V, et al. Effects of all-trans retinoic acid on renin–angiotensin system in rats with experimental nephritis. Am J Physiol Renal Physiol. 2001;281:909–19.
- Ballermann, BJ, Skorecki, KL, Brenner, BM (1984) Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am J Physiol 247: pp. 110-116
- Wilkes, BM (1987) Reduced glomerular angiotensin II receptor density in diabetes mellitus in the rat: time course and mechanism. Endocrinology 120: pp. 1291-1298 CrossRef
- O’Brien, RC, Cooper, ME, Jerums, G, Doyle, AE (1993) The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy. Diabetes 42: pp. 604-609 CrossRef
- Mahmood, J, Khan, F, Okada, S, Kumagai, N, Morioka, T, Oite, T (2006) Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney Int 70: pp. 1591-1598 CrossRef
- Azizi M, Menard J. Combined blockade of the renin–angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492–9.
- Mooser, V, Nussberger, J, Jullierat, L (1990) Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 15: pp. 276-282 CrossRef
- Orikasa, M, Matsui, K, Oite, T, Shimizu, F (1988) Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol 141: pp. 807-814
- Raij, L, Azar, S, Keane, W (1984) Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26: pp. 137-143 CrossRef
- Oyanagi-Tanaka, Y, Yao, J, Wada, Y, Morioka, T, Suzuki, Y, Gejyo, F (2001) Real-time observation of hemodynamic changes in glomerular aneurysms induced by anti-Thy-1 antibody. Kidney Int 59: pp. 252-259 CrossRef
- Wada, Y, Morioka, T, Oyanagi-Tanaka, Y, Yao, J, Suzuki, Y, Gejyo, F (2002) Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-Thy-1 glomerulonephritis. Kidney Int 61: pp. 432-443 CrossRef
- Kawamura, K, Okada, S, Li, B, Suwa, M, Yao, J, Morioka, T, Gejyo, F (2006) Turbulence of glomerular hemodynamics involved in progressive glomerulosclerosis. Kidney Int 69: pp. 1792-1798 CrossRef
- Jeunemaitre, X, Menard, J, Nussberger, J, Guyene, TT, Brunner, HR, Corvol, P (1989) Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 2: pp. 819-827
- Rahuel, J, Rasetti, V, Maibaum, J, Rueqer, H, Goschke, R, Cohen, NC (2007) Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 7: pp. 493-504 CrossRef
- Gradman, AH, Schimieder, RE, Lins, RL, Nussberqer, J, Chianq, Y, Bediqian, MP (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111: pp. 1012-1018 CrossRef
- Dietz, R, Dechend, R, Yu, CM, Bheda, M, Ford, J, Prescott, MF (2008) Effects of the direct rennin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 9: pp. 163-175 CrossRef
- Parving, HH, Person, F, Lewis, JB, Hollenberg, NK (2008) AVOID Study Investigators: aliskiren combined with losartan in type II diabetes and nephropathy. N Engl J Med 358: pp. 2433-2446 CrossRef
- Salomon SD, Appelbaum E, Manning WJ, Verma A, Berqlund T, Lukashevich V, Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertrophy. Circulation. 2009;119:530–7.
- Trimarchi, H (2011) Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis 4: pp. 41-48 CrossRef
- Wood, JM, Mailbaum, J, Rahuel, J, Grutter, MG, Cohen, NC, Rasetti, V (2003) Structure-based design of aliskiren, a novel orally effective rennin inhibitor. Biochem Biophys Res Commun 308: pp. 698-705 CrossRef
- Zou L-X, Imig JD, Von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 1996;28:669–77.
- Kobori, H, Prieto-Carrasquero, MC, Ozawa, Y, Navar, LG (2004) AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 43: pp. 1126-1132 CrossRef
- Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130–6
- Fischer, NDL, Danser, AHJ, Nussberger, J, Dole, WP, Hollenberg, NK (2008) Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117: pp. 3199-3205 CrossRef
- Apperloo, AJ, Zeeuw, D, Jong, PE (1997) A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51: pp. 793-797 CrossRef
- Weier MR. Acute fall in glomerular filtration rate with renin–angiotensin system inhibition: a biomeasure of therapeutic success? Kidney Int. 2011;80:235–7.
- Holtkamp, FA, Zeeuw, D, Thomas, MC, Cooper, ME, Graeff, PA, Hilleqe, HJ (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80: pp. 282-287 CrossRef
- Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis
Clinical and Experimental Nephrology
Volume 16, Issue 4 , pp 539-548
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Progressive glomerulosclerosis
- Direct renin inhibitor
- Local drug delivery
- Local renin–angiotensin system
- Industry Sectors
- Author Affiliations
- 1. Department of Cellular Physiology, Institute of Nephrology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
- 4. Department of Laboratory Medicine, National Center Hospital of Neurology and Psychiatry, Tokyo, Japan
- 2. Department of Cellular Biology, Institute of Nephrology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
- 3. Department of Clinical Engineering and Medical Technology, Niigata University of Health and Welfare, 1398 Shimami-cho, Kita-ku, Niigata, 950-3198, Japan